Orbit (Amsterdam, Netherlands) · 2021
Ophthalmic complications of immune checkpoint inhibitors.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wladis Edward J, Kambam Madhavi L
Аннотация
PURPOSE: Immune checkpoint inhibitors are a relatively new class of medications that activate normal tumor surveillance mechanisms. These agents have tremendous utility in treating a variety of cancers and are thus being used with increasing frequency. However, these medications carry significant ophthalmic toxicities. This review aims to discuss the most common ocular side effects of immune checkpoint inhibitors.
METHODS: A literature search was performed to identify reports of ophthalmic side effects of immune checkpoint inhibitors. The articles were reviewed, and data was extracted.
RESULTS: Immune checkpoint inhibitors may result in a wide variety of ophthalmic complications, including ocular surface disease, uveitis, orbital inflammation, myositis and myopathy, optic nerve disease, and chorioretinal lesions. While many of these toxicities respond to topical and systemic corticosteroids, more severe presentations necessitate temporary or permanent discontinuation of therapy.
CONCLUSIONS: This class of medication may yield a spectrum of ocular side effects, and ophthalmologists must be cognizant of these problems and their implications. Patient education facilitates appropriate vigilance and awareness of these issues. Coordination with the oncologic team will help to determine optimal treatment strategies.
METHODS: A literature search was performed to identify reports of ophthalmic side effects of immune checkpoint inhibitors. The articles were reviewed, and data was extracted.
RESULTS: Immune checkpoint inhibitors may result in a wide variety of ophthalmic complications, including ocular surface disease, uveitis, orbital inflammation, myositis and myopathy, optic nerve disease, and chorioretinal lesions. While many of these toxicities respond to topical and systemic corticosteroids, more severe presentations necessitate temporary or permanent discontinuation of therapy.
CONCLUSIONS: This class of medication may yield a spectrum of ocular side effects, and ophthalmologists must be cognizant of these problems and their implications. Patient education facilitates appropriate vigilance and awareness of these issues. Coordination with the oncologic team will help to determine optimal treatment strategies.